TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors.
TC BioPharm has raised $250K in total funding. The most recent round was Grant. The last funding was announced in November 2024.
TC BioPharm's investors include SyndicateRoom, Crowdcube, Genetix Biotherapeutics Inc., Scottish Enterprise, Nipro Corporation.
TC BioPharm is headquartered in Holytown, United Kingdom.
TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors.
TC BioPharm is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TC BioPharm — Funding & Investors." VCBacked, November 12, 2024, https://www.vcbacked.co/company/tc-biopharm. Accessed October 2, 2026.
VCBacked. (2024). TC BioPharm — Funding & Investors. Retrieved October 2, 2026, from https://www.vcbacked.co/company/tc-biopharm
{{cite web |title=TC BioPharm — Funding & Investors |url=https://www.vcbacked.co/company/tc-biopharm |website=VCBacked |access-date=October 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated